• Sigma upgrades FY25 normalised EBIT guidance to $64-$70 million
• Strong execution of new Chemist Warehouse supply contract
• Statutory NPAT impacted by non-recurring merger costs

Sigma Healthcare Limited has today upgraded its full year normalised EBIT guidance for the year ending 31 January 2025 to $64 to $70 million, up from the $50 to $60 million range previously guided in September 2024. The upgrade follows improved operational performance, including the strong execution of the new Chemist Warehouse supply contract that commenced on 1 July 2024, demonstrating the company's ability to efficiently absorb volume growth. However, subject to audit completion, Sigma's FY25 Statutory NPAT will be significantly impacted by non-recurring costs relating to the merger, including impacts of changes to existing performance rights as approved at the Sigma EGM. Sigma's full year audited results are anticipated to be released to the ASX in mid March 2025.

Sigma has upgraded its FY25 normalised EBIT guidance to $64-$70 million, up from the previous $50-$60 million range.